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Treatment of acute myeloid leukemia remains a therapeutic challenge. Even in younger patients with a low rate of
co-morbidities less than 50% of patients can be cured. For older patients or patients with significant co-morbidities,
the situation appears even worse. In patients not eligible for intensive treatment approaches - e.g. due to
underlying medical conditions - therapeutic approaches remain almost exclusively palliative. However, even with
less intense treatment approaches, temporary remission can be achieved and this contributes to prolonged survival
and improved quality of life of the respective patient. Targeted therapies have been widely used as palliative
treatment in- and outside clinical trials as single agents. Combination with low-dose cytarabine (LDAC) potentially
improves remission rates and can be safely administered in an outpatient setting.
Previous studies showed that additive hematologic toxicity of combinatory therapeutic approaches may arise from
simultaneous treatment (e.g. chemotherapy plus targeted therapies). However, sequential therapies have already
proven their feasibility in clinical trials. Here, we report two cases of rapid induction of complete molecular
remission by sequential therapy with LDAC and sorafenib in patients unfit for intensive chemotherapy without
significant long-term toxicity.
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Acute myeloid leukemia (AML) is an aggressive malignant
disease characterized by abnormal proliferation of imma-
ture hematopoietic cells. AML is the most frequent form
of acute leukemia in adults. Despite advances in chemo-
therapeutic treatment within the last decade, only 30-45%
of patients below the age of 60 can be cured. The majority
of patients, above the age of 60, have a dismal prognosis
with only 10-15% long-term survival [1-4]. While cytogen-
etic changes are established markers of prognosis and re-
sponse [5,6], several molecular markers have been defined
and analyzed for their prognostic influence [7,8]. Length-* Correspondence: Florian.Heidel@med.ovgu.de
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distribution, and reproduction in any mediummutations (or ‘internal tandem duplications’, ITD) of the
FLT3 tyrosine kinase occur in approximately one third of
adult patients with AML [7-9]. Clinically, the occurrence
of FLT3-ITD mutations in AML is associated with a higher
probability of relapse and shortened disease-free- and
overall-survival and therefore is considered as an unfavor-
able prognostic factor. FLT3-ITD mutations show a high
degree of heterogeneity with respect to their length, the
number of mutated clones, the allelic ratio of the dupli-
cated segments and the insertion sites. These variables may
have a dramatic impact on clinical outcome [10-14]. This
view is supported by gene expression profiling demonstrat-
ing that FLT3-ITD cases are a heterogeneous entity [15].
Using myelosuppressive chemotherapy regimens,
complete hematologic remission (CR) can be achieved
in 60-80% of patients below the age of 60. However,
the majority of patients with AML are above the agetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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do not benefit from myelosuppressive chemotherapy.
Using myelosuppressive chemotherapy, only 38-62%
of elderly patients reach CR and only 5-15% show
long-term overall survival compared to approximately
40% of younger patients. The prognosis is even worse
for patients who are not eligible for myelosuppressive
chemotherapy due to underlying medical conditions.
For those who are not eligible, less aggressive treatment ap-
proaches are clearly warranted. Using low-dose cytarabine
(LDAC) as monotherapy, a complete remission (CR) rate of
17% and a partial remission (PR) rate of 19% with a median
survival of 15 months could be shown in a meta-analysis
[16]. As this can be administered on an outpatient basis
and ‘reaching a remission’ as well as ‘outpatient treatment’
are known factors to significantly improve quality of life in
patients suffering from leukemia, LDAC can be considered
a feasible alternative. It has been demonstrated convin-
cingly, that outcome of LDAC treated patients is superior
to hydroxyurea treatment, however this benefit seems to be
restricted to cytogenetic subgroups [17]. The advantage in
overall survival corresponds to the achievement of a signifi-
cant remission and achievement of a CR also impacts qual-
ity of life in a positive manner. Several studies have been
conducted or are under way to determine the efficacy of
targeted agents in combination not only with intensive
[18-20] but also low dose chemotherapy [21,22]. Sorafenib
is one example of a multikinase inhibitor targeting FLT3-
receptor as well as BRAF, KIT and PDGFR that has been
investigated as monotherapy and in various combination
schedules. One important lesson learned from these trials
is, that toxicity may arise from concomitant treatment with
chemotherapy and targeted therapies. Combination of the
FLT3 kinase inhibitor sorafenib with myelosuppressive
[23,24] or low-dose chemotherapy [22] with overlapping
dosing schedules led to increased toxicity and required re-
duction of therapeutic medication. In contrast, sequential
therapy of chemotherapy with kinase inhibitors has already
proven its feasibility including a modest and acceptable tox-
icity rate [23].
Recent studies have substantially supported the concept of
FLT3-ITD as a valid therapeutic target in human AML, and
suggested that FLT3-ITD is capable of conferring a state of
‘oncogene addiction’, whereby cellular survival pathways as-
sociated with normal or precancerous cells can become
hijacked, leading to a state of reliance upon key signaling
molecules that can be exploited therapeutically [24]. There-
fore, targeting mutated FLT3-kinase in addition to standard
chemotherapy offered the opportunity to inhibit signaling
pathways crucially required for maintenance of AML. A se-
quential therapy schedule was chosen to avoid severe
hematologic toxicity as outlined above.
Here, we report on two cases of FLT3-ITD positive AML
in patients unfit for intensive chemotherapy being treatedwith sequential therapy consisting of LDAC followed by
oral administration of sorafenib resulting in rapid induction
of complete molecular remission with no significant toxicity
arising.
Case report 1
A 74-year old woman was referred from a county hospital
to our department in January 2013 with leukocytosis,
anemia and thrombocytopenia. She was in no apparent dis-
tress, however, presented on admission with reduced overall
physical fitness and kachexia (consistent with an ECOG-
score of 2). Laboratory findings presented as follows: Plate-
lets (PLT) 92 Gpt/l hemoglobin (HGB) 10.6 g/dl and white
blood count (WBC) 42.30 Gpt/l, with 5% neutrophils, 7%
lymphocytes, 1% eosinophils and 81% myeloid blasts. Bone
marrow aspiration confirmed the replacement of normal
hematopoiesis by blasts of myeloid morphology, FAB M2
(Figure 1, upper left panel). Karyotype analysis revealed a
normal female karyogram (46,XX) while molecular diag-
nostics was positive for an FLT3-length mutation (FLT3-
ITD) (Figure 2, lane 4). Her physical examination was
normal except a harsh 4/6 systolic murmur spreading to
the carotid arteries and over the precordium. Echocardiog-
raphy revealed a dilated left atrium and mild hypertrophy
of the left ventricle while demonstrating good ventricular
function (LVEF = 65%). The aortic valve appeared highly
stenotic (planimetric 0.9 cm2) and the mitral valve
presented with a modest stenosis of 1.8 cm2). Taken to-
gether, our patient was not eligible for intensive, myelosup-
pressive chemotherapy, as the necessary volume of infusion
therapy may have resulted in pulmonary edema and con-
gestive heart failure.
Therefore, we initiated palliative treatment using LDAC
at a dose of 20 mg BID for 10 days, followed by sorafenib
400 mg BID days 11–28 (Figure 3). The patient developed
severe (grade 3–4) but transient pancytopenia of less than
7 days and received six red blood cell transfusions and
three transfusions of platelets. By day 28 white blood
count and platelets appeared to be normalized with regu-
lar differentiation. Bone marrow aspiration performed on
day 28 (following the first cycle) showed regeneration of
the hematopoiesis with slight dysplasia but complete dis-
appearance of myeloid blasts (Figure 1, lower left panel).
PCR amplified FLT3-wildtype alleles with the mutated al-
leles no longer detectable (Figure 2, lane 5). The patient
remained in complete molecular remission with depend-
ency on red blood cell transfusions during the LDAC-
administration period.
Case report 2
A collaborating rehabilitation center referred a 58-year
old woman having suffered from a massive stroke of the
left hemisphere with consecutive right hemiplegia and
aphasia. In the past medical history, the husband
Figure 1 Cytomorphology of bone marrow (BM) aspirates at diagnosis and at remission controls obtained after the first cycle of
sequential therapy. Case 1 (left column): (i) Aspirate at primary diagnosis showing 80% BM infiltration with myeloid blasts. The malignant cells
show large nuclei, narrow cytoplasm and fine azurophilic granula. (iii) Complete remission (CR1) achieved after one cycle of low-dose cytarabine
(LDAC)/sorafenib. Differentiating granulopoiesis and reappearance of megakaryopoiesis as observed after reconstitution of peripheral blood
counts. Case 2 (right column): (ii) Predominant expansion of the erythroid lineage with pronounced dysplasia. The non-erythroid cells show 67%
of myeloid blasts consistent with the diagnosis of erythroleukemia (FAB M6). (iv) Reduction of cellularity and reconstitution of granulopoiesis
following the first cycle of sequential LDAC/sorafenib therapy. Achievement of complete hematologic remission with concomitant reconstitution
of peripheral blood counts.
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lipoproteinemia, diabetes and overweight of his wife for
several years resulting in myocardial infarction 10 years
ago and consecutive congestive heart failure. The massive
stroke became evident just weeks before admission. Dur-
ing rehabilitation blood counts were taken and revealed
profound anemia. The physiatrist referred the patient to
our department for red blood cell transfusion and diag-
nostic procedures.
On admission we saw an adipose woman with pro-
nounced hemiplegia, aphasia (consistent with an ECOG
score of 3). She appeared pancytopenic with a WBC of
1.61 Gpt/l, HGB of 9.5 g/dl and PLT count of 71 Gpt/l.
Bone marrow aspiration revealed pronounced hyperplasia
of erythropoiesis with severe signs of dysplasia (Figure 1,
right upper panel). Among the non-erythropoietic cells we
found 67% myeloid blasts, thus confirming diagnosis of
acute erythroleukemia (AML FABM6). The aspirate showed
a normal female karyotype (46,XX) and a PCR positive for
an FLT3-ITD mutation (Figure 2, lane 2).
In consent with the patient and her husband we initiated
palliative treatment using LDAC at a dose of 20 mg BID for
10 days, followed by sorafenib 400 mg BID days 11–28
(Figure 3). During the first cycle of LDAC the patient
remained leukopenic and developed neutropenic fever,
which resolved after empiric antibiotic treatment withmeropenem. Peripheral blood counts improved step-
wise during the second cycle of LDAC/sorafenib and
the peripheral blood counts normalized 6 weeks after
treatment initiation. Bone marrow aspiration confirmed
CR by cytomorphology (Figure 1, lower right panel) and
complete molecular remission (Figure 2, lane 3) by
PCR. The patient is currently under ongoing therapy in
an outpatient setting with a relapse free survival of
more than 290 days.
Discussion & review of the literature
Currently, sorafenib is not licensed for treatment of acute
myeloid leukemia (AML) but rather for treatment of he-
patocellular carcinoma or renal cell carcinoma. As a con-
sequence, sorafenib is not routinely prescribed on an
outpatient basis for AML. Despite these difficulties, sev-
eral reports have been published using sorafenib mostly as
a palliative treatment approach for relapsed and refractory
AML with a certain variability in response rates and
mostly hematologic toxicity.
Sorafenib has been investigated repeatedly as a single
agent for myeloid neoplasia. Within an early phase I dose
escalation trial 50 patients with advanced myelodysplastic
syndrome and/or refractory acute leukemia (AML, n = 48)
were treated with sorafenib monotherapy [25]. All patients
received a starting dose of 200 mg BID in 2 treatment arms:
Figure 2 PCR analysis at primary diagnosis and remission.
Standard diagnostic PCR was performed on DNA derived from
bone-marrow aspirates at primary diagnosis and remission. The PCR
assay used allows a sensitivity above 1:100 (as tested using MV4;11
cells as a positive control in comparison to healthy donor PBMC).
FLT3-ITD mutations were detectable in samples of both patients at
diagnosis (lane 2 - patient 2 and lane 4 - patient 1). Complete
molecular remission could be confirmed in both remission samples
(lane 3 - patient 2 and lane 5 - patient 1). MV4-11 cells served as
positive control (lane 7) and healthy donors or water as negative
controls (lane 6 and 8).
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and schedule (B) for 14 days every 21 days. The maximal tol-
erable dose (MTD)– due to hematologic toxicity - was found
to be at 400 mg sorafenib BID. The most common side ef-
fects were fatigue (58%), nausea/vomiting (44%) diarrhea
(36%) and dyspnea (30%). In terms of clinical responses, CR
or CR with incomplete recovery (CRi) of platelets could be
achieved in 10% of patients (n = 5). Moreover, 17 patients
(34%) revealed reduction of bone marrow- or peripheral
blood-blast count.
Man and colleagues recruited 13 patients with relapsed
or refractory FLT3-ITD positive AML to an open-label,
single-arm study [26]. Patients were treated with 200 or
400 mg sorafenib (BID) until either disease progression or
eligibility for hematopoietic stem cell transplantation
(HSCT). In this study, a high percentage of patients (6/13;0 10
LDAC 20mg s.c. / BID
Sorafenib
Figure 3 Treatment schedule. Sequential treatment with low-dose cytara
followed by sorafenib 400 mg p.o. BID days 11–28.46%) responded with CRi. In the context of HSCT, 65 pa-
tients with relapsed, chemotherapy-refractory FLT3-ITD
positive AML have been compiled for retrospective ana-
lysis [27]. Patients were categorized in two groups with one
group (n = 36) receiving conventional chemotherapy and
the second group (29 patients) receiving sorafenib as a sin-
gle agent for relapsed AML after allogeneic HSCT. In 42
patients sorafenib was given at a standard dose of 400 mg
BID. Frequently reported side effects included severe pan-
cytopenia (grade 3–4) in 40/65 patients (61.5%). Efficacy
was significantly lower compared to other reports cited
with 7.7% CR, 20% CRi and 44.6% of hematologic improve-
ment/blast response. Ten patients with a complete remis-
sion achieved also a complete molecular remission (CMR).
Overall response to sorafenib was comparable in a survey
analysis of 29 relapsed and refractory AML patients (with a
median age of 64.5 years) treated outside of clinical trials at
30 clinical centers in Germany [28]. Here, 6/23 patients
(21%) responded with CR (n = 2; 8.7%) or CRi (n = 4;
17.4%). The majority of these patients had intermediate
risk cytogenetics (93%) and showed positivity for
FLT3-length mutations (81%). Less than half of the pa-
tients were NPM1-mutated (43%). In most of the
reported patients (82%) sorafenib was given as a single
agent, while 18% received sorafenib in combination
with LDAC. Again, most prevalent toxicities included
cytopenia (in almost every patient) followed by nausea
and rash. By the time of the survey, 47% of patients
were alive at a median observation of 131 days. In all
other patients the median overall survival was 86 days
after initiation of sorafenib treatment. Overall survival
appears comparable or slightly below the results of
published data on palliative treatment with either hy-
droxyurea or LDAC [17] in patients considered unfit
for intensive chemotherapy at primary diagnosis.
Combination of LDAC with different ‘small molecules’
has been assessed in some clinical trials [21,22]. The com-
bination of LDAC with sorafenib has been recently inves-
tigated in a phase I/II trial for elderly patients with AML
or high-risk MDS [22]. Here, within the phase I sorafenib
was started at 200 mg BID days 2–28 followed by stepwise
increase of the dose level. LDAC was given at 10 mg s.c.
BID days 1–10. 13 patients were treated in phase I. Within20 28
 400mg p.o. / BID
bine (LDAC) 20 mg s.c. BID was conducted for 10 consecutive days
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of 600 mg days 2–28 and LDAC 10 mg s.c. BID days 1–10
to another 8 patients. Out of 15 evaluable patients two pa-
tients achieved a PR (13%) and CR (13%), respectively,
and two further patients (13%) showed a stable disease.
Given the combination of two effective drugs, the response
rate seemed significantly lower than the ones published in
previous reports, however, only 14% of patients revealed
FLT3-ITD mutations. The most frequent non-hematologic
toxicities were erythema multiforme, febrile neutropenia,
hypertension, tremor and fatigue of minor severity. How-
ever, severe hematologic toxicity (grade 3–4) occurred in
the vast majority of patients with 95% thrombocytopenia,
76% neutropenia and 62% anemia. This massive occurrence
of hematologic toxicity led to delay or reduction of therapy
and may be the consequence of increased sorafenib dosing
(up to 600 mg per day) contemporaneously administered
with LDAC. Taken together, response rates using sorafenib
as a single agent or in combination with low-dose chemo-
therapy have been reported in the range of 13-46% CR or
CRi, even when applied in relapsed or refractory disease.
Previous studies have investigated the relevance of mo-
lecular monitoring of FLT3-ITD mutations. Thiede and col-
leagues investigated a total of 979 FLT3-ITD mutated AML
patients treated with chemotherapy. Here, FLT3-ITD posi-
tive patients with high mutant/wildtype allelic ratio had a
dismal prognosis in regard to overall survival (OS) and dis-
ease free survival (DFS). Moreover, these patients had a sig-
nificant increased probability of relapse [12]. A second
study investigated in 11 cases with AML FLT3 mutations in
order to assess for minimal residual disease (MRD). MRD
was measured by single step real-time PCR. Five of eleven
patients developed positive MRD and all five patient MRD-
positive patients experienced relapse [29]. Upon sorafenib
treatment, two recent reports have assessed for residual dis-
ease on a molecular level [27,30]. Taken together, detection
of minimal residual disease has been assessed previously,
however, not systematically upon sorafenib treatment. Pa-
tients with high mutant/wt allelic ratio treated with
conventional chemotherapy seem to experience inferior
overall survival (OS) and disease free survival (DFS).
Positive MRD was associated with a significantly higher
risk of relapse. In our hands, combined treatment with
LDAC and sorafenib led to rapid induction of CMR in
both patients reported. Given the available data on
minimal residual disease after treatment with chemo-
therapy and targeted therapies, one can assume that
depth of response would correlate with improved over-
all survival and therefore would improve quality of life.
However, to the best of our knowledge, none of the pre-
vious publications investigating sorafenib for FLT3-ITD
mutated AML correlated the depth of response (CMR
versus CHR or PR) with overall survival and especially
quality of life. We believe that rapid induction of aCMR could eventually contribute to prolonged survival
and increased quality of life. From our perspective
these questions need to be addressed prospectively in
future clinical trials dealing with treatment of elderly,
frail or clinically challenged patients.
The two patients reported by us, immediately achieved
complete molecular remission after one cycle of sequential
therapy, consistent with excellent response rates of FLT3-
ITD positive cohorts published before. However, in the
literature responses are not exclusively restricted to FLT3-
mutated patients. In our hands this treatment approach
appeared to be safe, feasible and could be administered to
patients unfit for intensive chemotherapy in an outpatient
setting. Both patients reported a clear benefit in quality of
life and in both cases clinical responses were durable over
several months.
Overall, we conclude that sequential therapy with LDAC
followed by sorafenib appears to be an effective treatment
for patients unfit for intensive chemotherapy. Sequential
therapy was feasible even in an outpatient setting and did
not show substantial hematologic toxicity as anticipated by
simultaneous treatment approaches in recent clinical trials.
However, prolonged treatment over several cycles may de-
serve dose reduction or shortage of treatment days to avoid
hematologic toxicity, which is the major challenge of this
treatment approach. A larger sample size of patients will
have to be included in a prospective clinical trial to evalu-
ate this treatment strategy in detail.
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